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Abstract
Background: Functionalization is believed to have a considerable impact on the biodistribution of fullerene in vivo.
However, a direct comparison of differently functionalized fullerenes is required to prove the hypothesis. The
purpose of this study was to investigate the influences of surface modification on the biodistribution of fullerene
following its exposure via several routs of administration.
Methods: 13C skeleton-labeled fullerene C60 (
13C-C60) was functionalized with carboxyl groups (
13C-C60-COOH) or
hydroxyl groups (13C-C60-OH). Male ICR mice (~25 g) were exposed to a single dose of 400 μg of 13C-C60-COOH or
13C-C60-OH in 200 μL of aqueous 0.9% NaCl solution by three different exposure pathways, including tail vein
injection, gavage and intraperitoneal exposure. Tissue samples, including blood, heart, liver, spleen, stomach,
kidneys, lungs, brain, large intestine, small intestine, muscle, bone and skin were subsequently collected, dissected,
homogenized, lyophilized, and analyzed by isotope ratio mass spectrometry.
Results: The liver, bone, muscle and skin were found to be the major target organs for C60-COOH and C60-OH after
their intravenous injection, whereas unmodified C60 was mainly found in the liver, spleen and lung. The total
uptakes in liver and spleen followed the order: C60 > > C60-COOH > C60-OH. The distribution rate over 24 h followed
the order: C60 > C60-OH > C60-COOH. C60-COOH and C60-OH were both cleared from the body at 7 d post exposure.
C60-COOH was absorbed in the gastrointestinal tract following gavage exposure and distributed into the heart, liver,
spleen, stomach, lungs, intestine and bone tissues. The translocation of C60-OH was more widespread than that of
C60-COOH after intraperitoneal injection.
Conclusions: The surface modification of fullerene C60 led to a decreased in its accumulation level and distribution
rate, as well as altering its target organs. These results therefore demonstrate that the chemical functionalization of
fullerene had a significant impact on its translocation and biodistribution properties. Further surface modifications
could therefore be used to reduce the toxicity of C60 and improve its biocompatibility, which would be beneficial
for biomedical applications.
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Background
The physicochemical properties of nanomaterials, in-
cluding their size, shape, aspect ratio, charge, compos-
ition, surface chemistry and exposure route, may have a
significant impact on their molecular toxicity, cellular
uptake, transport/fate, absorption, distribution, metabol-
ism, excretion and toxicity in living organisms, thereby
affecting their applications in biomedicine [1–6]. The
surface modification of nanomaterials plays an essen-
tial role in improving their biocompatibility, regulat-
ing their in vivo distribution and metabolism, and
reducing their toxicity in the environment, which is
especially important for poorly soluble or insoluble
nanomaterials (e.g., carbon nanomaterials) [6–8]. Research
directed toward exploring the surface chemistries of car-
bon nanomaterials can be used to develop a better
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understanding of their novel properties and functions for
biomedical and numerous other applications [9–11]. For
example, the water-soluble derivatives of C60 have been de-
veloped for cancer treatment, antioxidation against oxida-
tive stress and free radicals, and bioimaging, etc. in
biomedical applications [9–11]. However, the unique prop-
erties of nanomaterials may also pose unexpected hazards
to human health and the environment [12–15]. The devel-
opment of simple, reliable and stable analytical methods for
the quantitative in vivo detection of nanomaterials is there-
fore critical to evaluate their biosafety and provide informa-
tion concerning nanofactor-relevant biological effects and
toxicity [16, 17]. Quantitative data pertaining to the charac-
teristics of nanomaterials may be beneficial for designing
safe and effective nanomaterials/nanodrugs, establishing
the predictive models of nanomaterials exposure, refining
the toxicological theories, developing a thorough under-
standing of nanotoxicology mechanisms and regulating risk
management strategies for nanomaterials [18, 19].
The development of efficient methods for the quantifi-
cation of carbon nanomaterials in vivo is quite rightly
regarded as the first and most important step in evaluat-
ing their biosafety [16]. The biodistribution of carbon
nanomaterials has been investigated extensively using a
diverse variety of quantification techniques [20]. Based
on a comparison of the results generated to date by
these different groups, it has been possible to devise
several guidelines concerning the pharmacokinetic and
biodistribution properties of carbon nanomaterials,
which have been communicated to the wider scientific
community [16, 20–24]. Among them, the surface func-
tionalization of carbon nanomaterials is believed to have
a significant influence on their biodistribution proper-
ties. For example, pristine carbon nanotubes (CNTs) and
PEGylated CNTs showed completely different blood cir-
culation and reticuloendothelial system (RES) accumula-
tion levels after intravenous administration [25–29].
In light of the difficulties associated with the
standardization of carbon nanomaterials, one could be
forgiven for viewing proposed regularities in the biodistri-
bution patterns of carbon nanomaterials obtained by com-
paring the results from different groups with some
suspicion [16]. Even identical materials prepared by differ-
ent groups using the same protocol can generate very dif-
ferent biodistribution data and considerable differences
may also be observed during the evaluation of otherwise
identical carbon nanomaterials by different labs. For in-
stance, Singh et al. and McDevitt et al. [30–33] independ-
ently reported the preparation of amino-CNTs using the
same protocol. While Singh et al. reported that the
amino-CNTs were rapidly cleared from the body, McDe-
vitt et al. reported much longer retention in RES organs.
There is therefore an urgent need for the development of
an analytical method for the direct quantitative
comparison of the biodistribution profiles of differently
functionalized carbon nanomaterials to address these
issues.
Fullerene C60 has a well-defined structure that can be re-
liably quantified by stable isotope labeling [34, 35]. Stable
isotope labelling avoids some of the drawbacks associated
with radioactive labeling, such as the requirement for radio-
active operating conditions and the generation of radio-
active wastes. Furthermore, the introduction of radioactive
or fluorophore tags can lead to pronounced changes in the
surface chemistry of nanomaterials, thereby altering their
transport and pharmacokinetic properties in vivo. In con-
trast, stable isotope 13C skeleton-labeled fullerene retains
the intrinsic properties of normal fullerene and its prepar-
ation does not require a radioactive protocol. Moreover,
stable isotopic tracers can be used to readily distinguish be-
tween the endogenous and exogenous sources of elemental
building blocks. Stable isotopic tracers are also beneficial
for differentiating between ultrafine carbon particles, car-
bon nanomaterials and carbon-rich biological samples with
similar compositions and dimensions [36–41]. The natural
abundance of 13C is 1.1% (atom ratio), which results in high
background 13C levels. However, the ratio of 13C to 12C
is constant in all living organisms, which means that
it does not interfere with the precision and accuracy
of the test. Stable 13C has been incorporated into the
carbon skeletons of numerous carbon nanomaterials,
and the transportation and transformations profiles
of the resulting isotope-labeled materials were read-
ily detected by isotope ratio mass spectrometry
(IRMS) [25, 29, 35, 42]. The enrichment or depletion
of 13C in a sample can be expressed using the delta
notation (δ13C) to a high level of precision (within
±0.1‰) [43, 44]. The quantitative comparison of dif-
ferently functionalized 13C-C60 materials could there-
fore provide a definitive understanding of the role
played by functionalization in the biodistribution of
carbon nanomaterials.
The primary aim of our study was to reveal the in-
fluence of surface functionalization on the biodistri-
bution of fullerene. In this study, we have prepared
13C skeleton-labeled fullerene (i.e., 13C-C60) materials
functionalized with carboxyl groups (13C-C60-COOH)
or hydroxyl groups (13C-C60-OH) (Fig. 1) and com-
pared their in vivo biodistribution profiles following
their administrations via three different exposure
pathways. C60-COOH and C60-OH showed differ-
ences in their biodistribution and body clearance
profiles after intravenous (i.v.) injection. C60-COOH
was mostly absorbed in the gastrointestinal tract,
whereas C60-OH was translocated throughout a var-
iety of different tissue types after intraperitoneal
(i.p.) injection. The results of this study have pro-
vided conclusive evidence that the chemical
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functionalization of carbon nanomaterials has a sig-
nificant impact on their translocation and biodistri-
bution behaviors.
Results
Characterization of C60-COOH and C60-OH
C60-COOH and C60-OH were both found to be highly
dispersible in water and other aqueous systems. Further-
more, brown dispersions of C60-COOH and C60-OH
were found to be stable for more than 6 months under
ambient conditions without any visible precipitation.
However, transmission electron microscopy (TEM) im-
ages revealed that very small aggregates were formed in
aqueous solutions of C60-OH and C60-COOH, with di-
ameters of 50 and 6–20 nm, respectively (Fig. 2). The
size distribution patterns of both samples in solution are
shown in Fig. 2b and d. The diameters of the C60-OH
and C60-COOH particles in water were around 62 and
120 nm, respectively. The hydrodynamic radii of both
samples were larger than the diameters observed in the
TEM images.
The infrared (IR) spectra of C60-COOH and C60-OH
were also collected to confirm that the functionalization
reactions had proceeded successfully (Fig. 3). The IR
spectrum of C60-COOH contained a broad peak at 3375
cm−1, which was attributed to the stretching vibrations of
the -COOH/-NH- groups. A tiny peak was also observed
at 2931 cm−1, which was attributed to the stretching vibra-
tions of the -CH2- groups. The peaks at 1644 and 1560
cm−1 were assigned to the stretching vibrations of the C =
Fig. 1 Structure of 13C-C60-COOH (left) and
13C-C60-OH (right). The
13C atoms (5 ~ 6 atoms per fullerene cage) were highlighted in green
Fig. 2 Representative TEM images (a, c) and size distribution patterns (b, d) of C60-COOH (a, b) and C60-OH (c, d)
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O and C = C moieties, respectively. Last, the characteristic
peak of the -COOH groups was observed at 1410 cm−1.
The IR spectrum of C60-OH contained a broad peak at
3406 cm−1 for the -OH groups, an intense peak at 1588
cm−1 for the C =C groups and a characteristic peak corre-
sponding to the bending vibrations of the -OH groups at
1393 cm−1. The differences in functionalities between C60-
COOH and C60-OH were also evaluated by X-ray photo-
electron spectroscopy (XPS). As shown in Fig. 4, the C1s
XPS spectrum of C60-COOH contained a strong C =O
peak at 288.0 eV, whereas the spectrum of C60-OH con-
tained a very weak C =O peak at 288.4 eV. The appear-
ance of C-O-C (285.6 eV) is a common phenomenon for
C60-OH. XPS demonstrated the chemical state of carbon
atoms. The lack of C-O in C60-COOH indicated that there
was no -OH in C60-COOH. Similarly, the very weak C =
O in C60-OH indicated that there was very limited or no
-COOH in C60-OH.
The 13C abundances of 13C-C60-COOH and
13C-C60-
OH were measured by IRMS. Urea was used as a work-
ing standard to calibrate the IRMS facility, which gave a
δ13C value of about -40.5573 ± 0.01106. The value deter-
mined for urea by IRMS was found to be equal to that
of the certified value for urea, indicating that our IRMS
system could be used to make reliable measurements.
The δ13C values for 13C-C60-COOH and
13C-C60-OH
were determined to be 7910.69 and 7914.92, respectively.
It is noteworthy that the δ values for 13C-C60-COOH
and 13C-C60-OH were much higher than that of the urea
standard value. Based on the equation for determining
the delta (δ) parameter [35, 43–45], the 13C abundances
(the atom percentage of 13C atoms per all carbon atoms
in a specific fullerene derivative) were calculated to be
about 8.204% ± 0.013% for 13C-C60-COOH and 8.310%
± 0.017% for 13C-C60-OH, equaling to 5.3
13C-atoms
per one 13C-C60-COOH and 5.0
13C-atoms per one
13C-C60-OH. The atom percentage of
13C reported for
the unmodified C60 in Ref. 35 was 8.752%. Collectively,
there were about 5 ~ 6 13C atoms per C60 cage, where
the 13C atoms were incorporated in the skeleton of
fullerene cage (Fig. 1). The amount of 13C found in the
two fullerene nanomaterials was around 9.0%, which is
higher than the weight percentage of 13C in natural
carbon (1.2% ± 0.0013%). All of these characterization
data indicated that the C60 derivative samples were suit-
able for the following in vivo quantification experiments.
Fig. 3 IR spectra of C60-COOH (black line) and C60-OH (red line)
Fig. 4 C1s XPS spectra of C -COOH (a) and C -OH (b)
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Biodistributions of C60-COOH and C60-OH after i.v.
injection
The biodistributions of C60-COOH and C60-OH were
studied following their i.v. injection in mice. C60-COOH
and C60-OH both showed low accumulation levels
(expressed as the percentage of the injected dose per
gram of tissue, %ID/g) in the bodies of the mice (Fig. 5).
The distributions of C60-COOH and C60-OH were de-
tected in the whole body with relatively high levels in
the liver, bone, muscle and skin tissues. The values ob-
tained for the accumulation of C60-COOH and C60-OH
in the RES organs in the current study were much lower
than those reported in our previous study for unmodi-
fied C60 (liver: 15.3%ID/g; spleen: 63.5%ID/g; lung:
18.2%ID/g) [35]. Furthermore, the value for C60-COOH
was slightly higher than that of C60-OH. During the first
5 min, it was clear that the distribution rate and accu-
mulation levels of C60-OH were higher than those of
C60-COOH. Considerable differences were observed in
the accumulation levels of C60-COOH and C60-OH in
the heart, liver, kidney, lung, small intestine and blood
tissue samples. Furthermore, higher levels of accumula-
tion were observed in the muscle and bone tissues for
both C60-COOH and C60-OH compared with the other
organs. The accumulation levels of C60-COOH and C60-
OH increased over time with the accumulation levels of
C60-COOH eventually catching up to those of C60-OH.
At 24 h, we observed almost identical levels of trapping
for C60-COOH and C60-OH, with very similar distribu-
tion patterns. C60-COOH resulted in slightly higher
levels of accumulation in the liver compared with C60-
OH following i.v. administration, whereas C60-OH re-
sulted in higher accumulation levels in the bone and
skin tissues. However, the only significant differences ob-
served between the accumulation levels of C60-COOH
and C60-OH were found in the bone. C60-COOH and
C60-OH were almost completely eliminated from the test
tissue samples at 7 d post exposure. Only low accumula-
tion levels were detected in some of the tissues at this
time point with no significant differences between the
difference materials and tissues (p > 0.05 compared with
the control group).
By multiplying the %ID/g data by the weights of the
organs or tissues, it was possible to obtain the corre-
sponding %ID (percentage of injected dose) data (Fig. 6).
The total uptakes in the liver and spleen were of the
order C60 > > C60-COOH > C60-OH. The distribution
rate at 24 h followed the order C60 > C60-OH > C60-
COOH. The liver and intestine were found to be the
major target organs for C60-COOH and C60-OH at 24 h
after i.v. injection, whereas unmodified C60 was mainly
found in the liver (23.75%ID), spleen (17.85%ID) and
lung (4.56%ID) [35]. It is noteworthy that the uptakes of
C60-COOH and C60-OH in bone and muscle were found
to be very large at 24 h, considering that the total
weights of the bone and muscle tissues were high. How-
ever, we did not obtain the %ID values for the bone and
muscle tissues because it was not possible to accurately
determine the weights of the bone and muscle tissues
and it would be unreasonable to infer that the accumula-
tion levels were the same in all of the bone and muscle
tissues.
The uptake levels in the liver, spleen and lung tis-
sues were further analyzed to reveal the accumula-
tions of C60-COOH and C60-OH in the RES organs.
A comparison of the RES uptakes of C60-COOH, C60-
OH and unmodified C60 is shown in Table 1 [35].
These results clearly show that the RES uptakes of
the C60 derivatives decreased considerably following
their functionalization. The uptake levels in the liver
and spleen followed the order C60 > > C60-COOH >
C60-OH. C60-COOH (9.1%ID) and C60-OH (8.2%ID)
showed much lower RES uptakes than C60 (46.0%ID)
[35]. Quantitatively, the hepatic accumulation of C60-
COOH (8.3%ID) was found to be slightly higher than
that of C60-OH (7.3%ID), whereas the spleen uptakes
of C60-COOH (0.33%ID) and C60-OH (0.27%ID) were
nearly the same. The level of C60-COOH accumula-
tion (0.44%ID) in lung was slightly lower than that of
C60-OH (0.64%ID), with both values being very low.
According to the Student t-test, the differences ob-
served between the unmodified C60 material and the
soluble derivatives at 24 h post exposure were signifi-
cant, suggesting that these surface modifications had
altered the RES uptake of fullerene.
Biodistributions of C60-COOH and C60-OH after gavage
and i.p. injection
The absorption and translocation properties of C60-
COOH and C60-OH varied considerably depending on
their route of administration (Fig. 7). For example, the
results revealed that C60-COOH showed high levels of
tissue accumulation following gavage administration,
with high concentrations of C60-COOH observed in the
stomach and intestine. Several other organs, including
the heart, liver, spleen, lung and bone, were also targeted
by this material. In contrast, the accumulation levels for
C60-OH were all rather low at less than 1.0%ID/g. How-
ever, these differences in the accumulation levels of C60-
COOH and C60-OH were found to be insignificant
because of the large variabilities observed in the experi-
ments, as well as the low accumulation levels.
Following i.p. exposure, C60-COOH was only detected
in the bone, spleen and kidneys at very low concentra-
tions, which indicated low levels of absorption in these
organs. In contrast, C60-OH translocated into a much
wider range of tissues after i.p. injection, including the
stomach, kidneys, lung, intestine, blood, muscle and
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Fig. 5 Biodistribution of C60-COOH (red columns) and C60-OH (blue columns) in mice after i.v. injection at different time points.
* p < 0.05
compared between C60-COOH and C60-OH
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Fig. 6 Uptakes of C60-COOH (red columns) and C60-OH (blue columns) in organs after i.v. injection at different time points.
* p < 0.05 compared
between C60-COOH and C60-OH
Wang et al. Particle and Fibre Toxicology  (2016) 13:14 Page 7 of 14
bone, where it showed high accumulation levels. Not-
ably, C60-OH was detected in tissues both in- and out-
side of the abdominal cavity. In a similar manner to
gavage exposure, the differences observed between C60-
COOH and C60-OH following i.p. exposure were deter-
mined to be insignificant.
Discussion
According to the experimental results described above,
the surface modification of fullerene nanomaterials led
to changes in their accumulation levels in specific or-
gans. At 24 h post exposure via i.v. administration, un-
modified C60 was found to be mainly distributed in the
liver, spleen and lung, whereas C60-COOH and C60-OH
were mainly trapped in liver, bone, muscle and skin fol-
lowing the same time period. These findings therefore
implied that the chemical functionalization of C60 with
carboxyl or hydroxyl groups resulted in the formation of
materials that could be eliminated from the liver or de-
posited in bone with greater ease than the parent
fullerene.
Low accumulation levels of C60-OH after i.v. adminis-
tration have also been reported by several other groups.
For example, Li et al. reported the biodistribution of
67Ga-C60(OH)x after i.v. exposure [46]. In this particular
case, the liver (12.9%ID/g), spleen (17.1%ID/g), skull
(23.7%ID/g) and thighbone (17.6%ID/g) showed rela-
tively high accumulation levels of the modified fullerene
at 24 h, whereas all of the other organs showed accumu-
lation levels of less than 4%ID/g. Using another radio-
active isotope 99mTc, Li et al. found that 99mTc-C60(OH)x
was distributed in the liver (9.4%ID/g), spleen (7.2%ID/g),
bone (8.4%ID/g), lung (1.7%ID/g), kidneys (5.2%ID/g),
intestine (2.1%ID/g) and heart (0.7%ID/g) of mice with
low accumulation levels at 24 h [47]. Similarly, Song et al.
reported that 99mTc(CO)3-C60(OH)20 distributed in the
whole body except for the brain, with accumulation levels
of less than 1.0%ID/g at 24 h [48]. Maksin et al. reported
the biodistribution of radiolabeled fullerenol after i.v.
exposure [49]. The results of this study revealed that full-
erenol was distributed into the lung (2.1%ID), liver
(20.1%ID), kidney (5.3%ID), muscle (0.16%ID/g), bone
(0.59%ID/g), thyroid (0.2%ID), spleen (0.66%ID) and intes-
tine (16%ID) at 2 h. Li et al. reported the biodistribution
of C60(OH)x(O)y after i.v. exposure, and showed that full-
erenol was distributed into the heart, lung, liver, spleen,
kidney, muscle, bone, intestine, fur and brain [50]. Fur-
thermore, relatively high accumulation levels were found
in the liver (4.3%ID/g), spleen (2.3%ID/g), kidney (4.1%ID/
g) and bone (8.0%ID/g) at 24 h post exposure. Ji et al. la-
beled C60(OH)x with
125I and followed the translocation of
125I-C60(OH)x in tumor-bearing mice [51]. The results
showed that 125I-C60(OH)x was distributed through the
whole body of the mice, except for their brain, and that
relatively high accumulation levels were found in the liver
(2.0%ID/g), stomach (1.2%ID/g), kidney (1.6%ID/g) and
bone (1.7%ID/g) at 24 h. These results from the literature
therefore confirm the reliability of our distribution results
for C60-OH. Furthermore, based on the experimental re-
ports described above, it is clear that the surface hydroxyl-
ation of C60 leads to improved water-solubility and
bioavailability. These changes also enhance the ability of
these materials to cross biological barriers in vivo, and
therefore reduce the accumulation and retention levels of
these compounds in the tissues/organs.
Furthermore, hydroxylation led to slightly lower levels
of RES capture than those encountered following the
carboxylation of the fullerene core. The low RES capture
of C60-OH observed in this study was consistent with
the results of several other studies. For example, 67Ga-,
125I- and 99mTc-labeled fullerenols all showed low levels
of RES capture [46–51]. Pristine C60 nanoparticles are
hydrophobic xenobiotic substances, which are easily
trapped in the RES organs as part of an organism’s
natural defense mechanism. While surface chemical
modifications can lead to enhanced hydrophilicity and
biocompatibility properties in fullerene nanomaterials, as
well as enhancing their ability to cross biological barriers
in mice, they can also lead to reduced uptake into the
RES organs.
Our biodistribution results for C60-COOH were differ-
ent from those reported by Yamago’s group [52]. In
Yamago’s study, C60 was functionalized via a cycloadd-
ition reaction with dipolar trimethylenemethane to give
a water-soluble fullerene derivative bearing terminal
carboxyl groups. These fullerene derivatives were pre-
dominantly trapped in the liver (91.7%ID at 16 h), with
the accumulation levels in the heart, spleen, lung, kid-
neys, brain and testicles being much lower. The differ-
ence between our results and those of Yamago’s groups
could be attributed to differences in the functionaliza-
tion density and the length of chains attached to the
carboxylic acid groups. In our study, each fullerene cage
had two carboxyl groups, which were directly linked on
the pyrrolidine ring. In Yamago’s study, each fullerene
cage had only one carboxyl group, which was linked to
the five-membered ring with a small linker. The solubil-
ity of C60-COOH was therefore much higher than that
Table 1 Uptakes of C60-COOH, C60-OH and unmodified C60 in
RES organs after i.v. injection 24 h
C60-COOH (%ID) C60-OH (%ID) Unmodified C60 (%ID)
a
Liver 8.35 ± 2.37 7.27 ± 1.26 23.75 ± 3.81*,§
Spleen 0.33 ± 0.01 0.27 ± 0.10 17.85 ± 4.35*,§
Lung 0.44 ± 0.23 0.64 ± 0.23 4.56 ± 1.96*,§
a The data of unmodified C60 are from our previous study in reference [35].
* p
< 0.05 between C60-COOH and unmodified C60;
§ p < 0.05 between C60-OH and
unmodified C60
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of the fullerene derivatives described in Yamago’s study.
The lower hydrophilicity of Yamago’s compounds would
lead to higher levels of protein binding. Yamago’s fuller-
ene derivatives would also be recognized by opsonin and
more easily trapped in the RES organs.
The surface functionalization of fullerene also affected
its bioavailability and distribution following the gavage
and i.p. administration routes, although the differences
observed in these cases were not found to be significant
because of their low accumulation levels. The high ab-
sorption of C60-COOH following gavage exposure could
be attributed to the hydrophobicity of the fullerene cage
and the small size of the C60-COOH aggregates. There
have been several reports in the literature that show that
small nanoparticles with good hydrophobicity show high
bioavailability after oral exposure [53–59]. However, fol-
lowing i.p. exposure, the tissue translocation of C60-OH
was much more widespread and pronounced than that of
C60-COOH. The low translocation of C60-COOH ob-
served in this case could be attributed to the negative
charges on the carboxylate groups and its hydrophobicity.
The free translocation of hydroxylated carbon nanomater-
ials has also been observed for CNTs. For example,
Wang’s group reported that hydroxylated CNTs were
detected in the whole body after i.p. injection [60, 61].
The results of the current study suggest that the transloca-
tion and distribution properties of functionalized fuller-
enes are regulated by their surface-modified groups.
Moreover, accumulated fullerene derivatives could be
cleared from the body during long-term observations,
since the i.v. injection data clearly indicated that the fuller-
ene derivatives had been cleared completely at 7 d post
exposure.
Mechanistically, how the surface regulates bioavailability
and biodistribution might be related to the opsonization
of fullerene. It is well known that nanoparticles entering
systemic circulation can be tagged with opsonin. The sub-
sequent recognition of opsonin can lead to these nanopar-
ticles being captured by phagocytic cells in the RES
organs. We previously demonstrated that surface functio-
nalization can affect the interactions formed between
fullerenes and proteins [62, 63]. For example, increasing
the degree of functionalization (hydroxylation) led to a de-
crease in the extent of several fullerene–protein interac-
tions, most likely because of the reduced opsonization of
C60-OH. The lower accumulation levels of C60-COOH
and C60-OH could therefore be attributed to reduced
levels of opsonization following their surface modification.
Fig. 7 Translocation and biodistribution of C60-COOH (red columns) and C60-OH (blue columns) in mice at 24 h after gavage and i.p. exposures
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It is noteworthy that C60-COOH and C60-OH formed
different-sized aggregates because of the differences in
their functionalization. The differences in the sizes of
these aggregates could also affect their biodistribution
behaviors. However, the influence of their size would be
much less pronounced in this case, because the particu-
late sizes of C60-COOH and C60-OH were smaller than
the pulmonary capillary diameter. When particulate size
is smaller than the pulmonary capillary diameter, the
particles can escape pulmonary filtration and be cap-
tured by the RES via opsonization [20, 21]. Opsonization
is mainly dependent on the surface of a given nanoma-
terial, whereas particle size plays a much smaller role.
It is also noteworthy that the accumulation levels of
C60-COOH and C60-OH found in bone and muscle
(hind leg) were both relatively high following short-term
observation (up to 24 h), suggesting that the total
amounts of accumulation in bone and muscle were
large. To estimate the total uptakes, we assumed that
the accumulation levels in whole bone, muscle and
skin were homogenous and that the tissue indices
(tissue weight/body weight) were 10, 25 and 10% for
bone, muscle and skin, respectively. The bone uptake
was 25 ± 3%ID for C60-COOH and 36 ± 1%ID for C60-
OH. The muscle uptake was 48 ± 21%ID for C60-
COOH and 40 ± 3%ID for C60-OH. The skin uptake
was 14 ± 3%ID for C60-COOH and 21 ± 5%ID for C60-
OH. The percentage of C60-COOH increased from
42%ID at 5 min to 112%ID at 24 h, whereas the per-
centage of C60-OH increased from 45%ID at 5 min to
123%ID at 24 h. This implied that both C60-COOH
and C60-OH were rapidly cleared from the blood and
distributed in the interstitial fluid, from which point
they gradually migrated into the organs and tissues
during the first 24 h. The total percentages at 24 h
were all larger than 100%ID, suggesting that while
our original estimation was inaccurate, the trends
(not the accurate values) were meaningful.
The results of the current study clearly show that the
functionalization shifted the uptake of fullerene from the
RES organs to the soft tissue and skeleton. Similar
trends to this have been reported elsewhere in the litera-
ture, where the hydroxylation of fullerene led to high
levels of accumulation in the bone and muscle tissues
[46–51]. These differences could be attributed to the
functionalized fullerenes being better equipped to escape
capture by the RES and more capable of making their
way into the soft tissues and bone. The retention of
these fullerene derivatives in the body remained transi-
ent, with no statistically significant levels of accumula-
tion being detected after 7 d. From a toxicological
perspective, this shift in the accumulation of fullerene
derivatives from the RES toward the soft tissues and
bone would definitely have an impact on their toxicity.
Reduced levels of RES capture would relieve the toxicity
of fullerenes toward the liver, lung and spleen, although
the translocation of these materials to other organs and
tissues could lead to toxicity elsewhere. The good news
in this case is that these fullerene derivatives were rap-
idly cleared from the body. The long-term toxicities of
fullerene derivatives could be lower than those of the
corresponding pristine materials. Future studies should
therefore focus on the toxicological evaluation of pris-
tine and functionalized fullerene systems to develop a
better understanding of the toxicological impact of
functionalization.
Conclusions
In summary, we have quantitatively investigated the im-
pact of different surface modifications and routes of ad-
ministration on the biodistribution of fullerene in vivo
using a 13C-labeled carbon cage tracer. We specifically
compared the biodistribution behaviors of C60-COOH
and C60-OH in mice following their exposure via three
different pathways, where C60-COOH and C60-OH
showed distinct distribution patterns. The surface modi-
fication of fullerene C60 led to a decrease in its accumu-
lation and rate of distribution, as well as altering its
target organs. These differences clearly indicated that
the chemical functionalization of fullerene has a signifi-
cant influence on its translocation and biodistribution.
In particular, the differences between C60-COOH and
C60-OH were more distinguishable following gavage and
i.p. administration. Undoubtedly, specific surface modifi-
cations could lead to improvements in the biocompati-
bility of C60, by reducing its toxicity, which could be of
some benefit in terms of the biomedical application of
these materials. We therefore believe that our results
could benefit specific biomedical applications, as well as




Amorphous carbon powder of 99% 13C was purchased
from Cambridge Isotopes Laboratories, Inc. (Andover,
MA, USA). 13C-C60 was prepared using the arc dis-
charge method according to our previously reported
procedure [34, 35]. Unlabeled C60 was obtained from
Nanjing XFNANO Materials Tech Co., Ltd (Nanjing,
China). All of the other chemicals used in this study
were purchased as the analytical degree from various
chemical suppliers.
Preparation of 13C-C60-COOH and
13C-C60-OH
The carboxylation of 13C-C60 was conducted according
to a modified version of the method reported by Gan et
al [64]. Briefly, Me2HNCH2COOEt•HCl (279 mg, 2.0
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mmol) and sodium hydroxide (228 mg, 5.7 mmol) were
added to 15 mL of methanol, and the resulting mixture
was stirred until it formed a solution. This solution was
then added to a solution of 13C-C60 in toluene (60 mL),
and the resulting mixture was irradiated with a nonde-
structive xenon lamp (300 W) under continuous stirring
for 1 h, during which time the solution changed color
from purple to brown. The solution was then con-
centrated under reduced pressure to approximately
20 mL and treated with sodium hydride (1 g), before
being heated at 70 °C under continuous stirring for
6 h. The mixture was then cooled to room
temperature and added to 10 mL of methanol before
being evaporated to dryness under reduced pressure
to give a residue. The residue was then added to
water (50 mL) to dissolve the 13C-C60-COOH, and
the resulting suspension was centrifuged (3000 × g, 5 min).
The supernatant was then collected and purified by
column chromatography over Sephadex G-25 gel to
separate the desired 13C-C60-COOH material from
any unwanted small molecules. The first fraction
was collected and lyophilized to give 13C-C60-
COOH.
The hydroxylation of 13C-C60 was conducted according
to a procedure from the literature [65–67]. Briefly, a
toluene solution of 13C-C60 was vigorously stirred
with powdered NaOH and 50% tetrabutylammonium
hydroxide (TBAH) at room temperature in an open
vessel for 24 h. The biphasic reaction mixture was
then separated and the aqueous phase was filtered to
remove trace quantities of water-insoluble residues.
The filtrate was then added with methanol, which re-
sulted in the formation of a brown precipitate. The
methanol was subsequently removed in vacuo to give
a residue, which was dissolved in water and purified
by column chromatography over Sephadex G-25 gel
(1 × 30 cm) eluting with neutralized water. Fractions
containing the desired product were freeze-dried to
give 13C-C60-OH as a yellow powder.
The 13C-C60-COOH and
13C-C60-OH samples gen-
erated above were characterized by IRMS (Thermo-
Fisher Delta V advantage; Waltham, MA, USA), TEM
(Tecnai G2 F20 U-TWIN; Hillsboro, Oregon, USA),
Nanosizer analysis (Nanobrook-Omni, Bruker; Holts-
ville, New york, USA), IR spectrometry (Mir-IR, Nico-
let iN10 MX, ThermoFisher; Waltham, MA, USA) and
XPS (Thermo Scientific ESCALab250Xi; Waltham,
MA, USA).
Animal administration
Animal experiments were performed humanely in ac-
cordance with the Animal Care and Use Program
Guidelines of the Sichuan Province, China. Male ICR
mice (25 g) were obtained from Sichuan University
Animal Center, Chengdu, China. The mice were raised
in plastic cages (three mice/cage) on a 12-h light/dark
cycle with ad libitum access to food and water. Fol-
lowing acclimation, the mice were randomly divided
into 15 groups (three mice for each group) for the bio-
distribution studies.
Biodistributions of 13C-C60-COOH and
13C-C60-OH after i.v.
injection
The mice were injected via their tail vein with 13C-C60-
COOH or 13C-C60-OH at a single dose of 400 μg in 200
μL of 0.9% aqueous NaCl solution. Blood samples were
collected periodically from the mice, which were subse-
quently scarified at designated time intervals. Several tis-
sue samples, including heart, liver, spleen, stomach,
kidney, lung, brain, large intestine, small intestine, bone
(hind leg), muscle (hind leg) and skin (abdomen), were
collected from the mice and dissected, homogenized and
lyophilized before being analyzed by IRMS using our
previously reported procedure [35]. The control animals
were injected with 200 μL of 0.9% aqueous NaCl solu-
tion and sampled in the same way. The results of these
analyses have been presented as %ID/g values for all of
the tissue samples, as well as %ID values for the heart,
liver, spleen, stomach, kidneys, lungs, brain, large intes-
tine and small intestine samples.
Translocation profiles of 13C-C60-COOH and
13C-C60-OH
after gavage and i.p. administration
For gavage exposure, the mice were exposed to 13C-C60-
COOH or 13C-C60-OH at a single dose of 400 μg in 200
μL of 0.9% aqueous NaCl solution via gavage. For i.p. ex-
posure, the mice were intraperitoneally injected with
13C-C60-COOH or
13C-C60-OH at a single dose of 400
μg in 200 μL of 0.9% aqueous NaCl solution. The con-
trol groups were exposed to 200 μL of 0.9% aqueous
NaCl solution according to the same protocols as those
described above. All of these animals were sampled in
the same way as those subjected to the i.v. injection
protocol.
IRMS analyses
The IRMS measurements and calculations were per-
formed as follows. The IRMS system was calibrated
using a standard urea sample (traceable to primary iso-
topic certified reference materials issued by the Inter-
national Atomic Energy Agency, Vienna), because
Vienna Pee Dee Belemnite (VPDB) was too expensive
and only available in limited amounts. The calibration
was satisfied when the value determined using our sys-
tem matched that of the certified value. Whole organs
or tissue samples obtained from the 13C-fullerene ex-
posed mice were dissected and weighted. The liver and
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intestinal samples, which were too large to fit into the
homogenizer, were cut into small pieces (smaller than 1
mm in diameter) with scissors and 0.5-g samples of
these materials were mixed with 2.0 mL of water. All of
the other organ/tissue samples were less than 0.5 g in
weight and could therefore be added directly to 2.0 mL
of deionized water. The samples were then thoroughly
homogenized in a homogenizer. The homogenates were
subsequently lyophilized to obtain dry powders, which
were analyzed by IRMS. The IRMS results were obtained
in the form of δ values, which were subsequently con-
verted into 13C/12C ratios (r) following Equation 1.
[(13C/12C)standard] was the
13C/12C ratio of the VPDB
sample (0.0112372). Because VPDB is classical for IRMS,
the calculation still refers to VPDB in the literature,
where the calculating results would not be interfered by
the different calibration references [36, 37]. The r values
were then converted into percentages of 13C in mass (ω13C )
using Equation 2, which provided the ratio of “total weight
of 13C atoms/total weight of carbon atoms”. The mass of
13C-enriched fullerene derivatives in each tissue (m13C−fullerene )
was determined using Equation 3, where the ωcarbon of tissue
value determined by IRMS was the mass percentage of car-
bon in the dry tissue samples from the exposed and unex-
posed mice (the value was constant for certain organs);
mtissue was the weight of tissues; mdry/mwet was the weight
ratio of the tissue samples before and after drying, which
was measured using unexposed mice and was constant for
certain organs; ω13C tissueð Þ was the mass percentage of 13C
in each tissue sample from the exposed mice; ω13C controlð Þ
was the percentage of 13C in mass for tissue samples from
the unexposed mice; and ω13C−fullerene was the percentage of
13C in the 13C-enriched fullerene derivatives. The content
of each 13C-enriched fullerene derivative was expressed as
%ID/g (Equation 4) or %ID (Equation 5), where the dose
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All data have been expressed as the mean values of three
individual observations together with the associated
standard deviation (mean ± SD). Significant differences
between the biodistribution data of C60-OH and C60-
COOH were calculated using the Student’s t-test. Differ-
ences were considered significant for p < 0.05. Compari-
sons were made in a time-dependent manner between
the different exposure pathways. The %ID data of 13C-
C60-OH and
13C-C60-COOH were compared with those
of the unmodified C60 to reveal the impact of the surface
functionalization on the biodistribution of fullerene.
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